<p><strong>Pediatric Use</strong>: Safety and effectiveness of Iron Sucrose in pediatric patients have not been established.<br />
<br />
<strong>Geriatric Use</strong>: No overall differences in safety were observed between the elder subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.<br />
<br />
<strong>Injection into dialyser</strong>: Iron Sucrose Injection may be administered directly into the venous limb of the dialyser under the same conditions as for intravenous injection.<br />
<br />
<strong>Hemodialysis Dependent-Chronic Kidney Disease Patients (HDD-CKD)</strong>: Iron Sucrose Injection may be administered undiluted as a 100 mg slow intravenous injection over 2 to 5 minutes or as an infusion of 100 mg, diluted in a maximum of 100 ml of 0.9% NaCI over a period of at least 15 minutes per consecutive hemodialysis session for a total cumulative dose of 1,000 mg.<br />
<br />
<strong>Non-Dialysis Dependent-Chronic Kidney Disease Patient (NDD-CKD)</strong>: Iron Sucrose Injection is administered as a total cumulative dose 1000 mg over a 14 day period as a 200 mg slow IV injection undiluted over 2 to 5 minutes on 5 different occasions within the 14 day period.</p>